It has been evaluated the utility of using genetic information to personalize the prescription of medicines in the context of several medical fields, demonstrating that patients whose doses are adjust...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
The company Chemotargets –based in the Barcelona Science Park and a leader in in the global market as a provider of intelligence and drug design prediction platform– has signed a strategic agreeme...
A very recent study published in the scientific journal PNAS highlights an estimate, on a global scale, of the frequency of individuals carrying pathogenic mutations responsible for inherited re...
Results show that in order to treat patients efficiently, it is necessary to know the specific molecular characteristics of their cancer, such as TGF-β and EGF receptor expression levels